Abstract 526P
Background
Tracheal, Bronchus, and Lung (TBL) cancer is the 1st leading cause of deaths across Southeast Asia (SEA), East Asia (EA), and Oceania (OC). However, there has been a lack of estimates regarding the burden of TBL cancer across these regions in previous studies.
Methods
Utilizing the Global Burden of Disease Methodology, TBL cancer prevalence, incidence, mortality, and disabiity adjusted life years (DALYs) were analyzed by age, sex, year, across SEA, EA, and OC spanning from 1990-2019. We employed a regression framework to forecast TBL cancer deaths through 2040.
Results
The total prevalence of TBL cancer cases surged by 3.5 times, escalating from 344,251 (95% uncertainty interval: 301,687-388,590) in 1990 to 1,306,745 (1,116,313-1,513,254) in 2019. While deaths rose from 319,128 (282,904-359,206) to 914,442 (791,095-1,049,894) from 1990-2019. In terms of the age-standardized incidence rate (ASIR), there was an increase from 27.81 (24.65-31.15) to 37.13 (32.08-42.53) per 100,000 person years from 1990-2019. The highest annual percentage of change (APC) was witnessed in deaths, rising by 187%, and in DALYs, increasing by 143% from 1990-2019. Notably, China experienced the highest APC in ASIR (38%), followed by Indonesia (35%), and Taiwan (28%) from 1990-2019. Meanwhile, Indonesia exhibited the highest increase in age-standardized mortality rate (ASMR) at 36%, while the Maldives demonstrated the most notable decrease of 33% from 1990-2019. In 2019, individuals aged 65-69 accounted for the highest incidence (172,031), while those aged 70-74 saw the highest mortality (155,538). Moreover, male individuals consistently bore a greater burden than females over the past three decades. Projection indicates that the total number of deaths may reach 1,080,050 (705,751-1,800,670) by 2040.
Conclusions
TBL cancer constituted 26.21% of all deaths within the realm of cancer-related fatalities in SEA, EA, and OC in 2019. This study uncovers a consistent pattern of escalating burden, emphasizing a notable rise in fatalities and its implications for public health, necessitates comprehensive strategies that encompass both individual risk factors and systemic challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract